A PHASE II TRIAL WITH BEVACIZUMAB AND IRINOTECAN FOR PATIENTS WITH PRIMARY BRAIN TUMORS AND PROGRESSION AFTER STANDARD THERAPY

被引：0

作者：

Moller, Soren ^{[1
]}

Grunnet, Kirsten ^{[1
]}

Hansen, Steinbjorn ^{[2
]}

Schultz, Henrik ^{[3
]}

Holmberg, Mats ^{[4
]}

Sorensen, Morten M. ^{[1
]}

Poulsen, Hans S. ^{[1
]}

Lassen, Ulrik ^{[1
]}

机构：

[1] Rigshosp, Copenhagen Univ Hosp, Copenhagen, Denmark

[2] Odense Univ Hosp, Odense, Denmark

[3] Aarhus Univ Hosp, Aarhus, Denmark

[4] Aalborg Univ Hosp, Aalborg, Denmark

来源：

NEURO-ONCOLOGY | 2010年 / 12卷

关键词：

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

引用

页码：73 / 73

页数：1

共 50 条

[1] A phase II trial with bevacizumab and irinotecan for patients with primary brain tumors and progression after standard therapy
Moller, Soren
Grunnet, Kirsten
Hansen, Steinbjorn
Schultz, Henrik
Holmberg, Mats
Sorensen, Morten
Poulsen, Hans S.
Lassen, Ulrik
ACTA ONCOLOGICA, 2012, 51 (06) : 797 - 804
[2] A phase II trial with cetuximab, bevacizumab, and irinotecan for patients with primary glioblastomas and progression after radiation therapy and temozolamide
Lassen, U.
Hasselbalch, B.
Sorensen, M.
Holmberg, M.
Hansen, S.
Kosteljanetz, M.
Laursen, H.
Poulsen, H. S.
JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
[3] Cetuximab, bevacizumab, and irinotecan for patients with primary glioblastoma and progression after radiation therapy and temozolomide: a phase II trial
Hasselbalch, Benedikte
Lassen, Ulrik
Hansen, Steinbjorn
Holmberg, Mats
Sorensen, Morten
Kosteljanetz, Michael
Broholm, Helle
Stockhausen, Marie-Therese
Poulsen, Hans Skovgaard
NEURO-ONCOLOGY, 2010, 12 (05) : 508 - 516
[4] A PHASE II TRIAL WITH CETUXIMAB, BEVACIZUMAB AND IRINOTECAN FOR PATIENTS WITH PRIMARY GLIOBLASTOMAS AND PROGRESSION AFTER RADIATION THERAPY AND TEMOZOLOMIDE
Hasselbalch, Benedikte
Lassen, Ulrik
Soerensen, Morten
Holmberg, Matts
Hansen, Steinbjoern
Kosteljanetz, Michael
Broholm, Helle
Poulsen, Hans Skovgaard
NEURO-ONCOLOGY, 2008, 10 (05) : 828 - 828
[5] Phase 2 study of carboplatin, irinotecan, and bevacizumab for recurrent glioblastoma after progression on bevacizumab therapy
Reardon, David A.
Desjardins, Annick
Peters, Katherine B.
Vredenburgh, James J.
Gururangan, Sridharan
Sampson, John H.
McLendon, Roger E.
Herndon, James E., II
Coan, April
Threatt, Stevie
Friedman, Allan H.
Friedman, Henry S.
CANCER, 2011, 117 (23) : 5351 - 5358
[6] A phase I/II trial of irinotecan and whole brain radiation therapy in patients with brain metastases.
Chen, AY
Ryu, JK
Lau, D
JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (16) : 127S - 127S
[7] Phase II trial of bevacizumab, irinotecan, cisplatin, and radiation as preoperative therapy in esophageal adenocarcinoma
Ilson, David
Goodman, Karyn A.
Janjigian, Yelena Yuriy
Shah, Manish A.
Kelsen, David Paul
Rizk, Nabil P.
Rusch, Valerie W.
Wu, Abraham Jing-Ching
Campbell, Jenny
Capanu, Marinela
Bains, Manjit S.
JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
[8] Phase II Trial of Single-Agent Bevacizumab Followed by Bevacizumab Plus Irinotecan at Tumor Progression in Recurrent Glioblastoma
Kreisl, Teri N.
Kim, Lyndon
Moore, Kraig
Duic, Paul
Royce, Cheryl
Stroud, Irene
Garren, Nancy
Mackey, Megan
Butman, John A.
Camphausen, Kevin
Park, John
Albert, Paul S.
Fine, Howard A.
JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (05) : 740 - 745
[9] A Phase II Trial of Irinotecan and Cisplatin in Patients with Metastatic Neuroendocrine Tumors
Matthew H. Kulke
Bingyan Wu
David P. Ryan
Peter C. Enzinger
Andrew X. Zhu
Jeffrey W. Clark
Craig C. Earle
Ann Michelini
Charles S. Fuchs
Digestive Diseases and Sciences, 2006, 51 : 1033 - 1038
[10] A phase II trial of irinotecan and cisplatin in patients with metastatic neuroendocrine tumors
Kulke, Matthew H.
Wu, Bingyan
Ryan, David P.
Enzinger, Peter C.
Zhu, Andrew X.
Clark, Jeffrey W.
Earle, Craig C.
Michelini, Ann
Fuchs, Charles S.
DIGESTIVE DISEASES AND SCIENCES, 2006, 51 (06) : 1033 - 1038

← 1 2 3 4 5 →